Head-to-head evidence
Fulzerasib vs Glecirasib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: KRAS G12C · full Non-Small Cell Lung Cancer pipeline
Fulzerasib
Developed by Innovent Biologics
NCT05756153 · Phase 1/2 · completed
The study was open-label, non-randomized, and had no comparator arm, with 47 participants. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Interim analysis (ASCO 2024 late-breaking presentation, data cutoff before primary completion); single-arm response rate with no formal statistical threshold.
Next expected readout: March 2027 · NCT07492342 (registry estimate)
Glecirasib
Developed by Jacobio Pharmaceuticals
NCT05002270 · Phase 1/2 · completed
The study was a small, non-randomized, open-label trial without a comparator, evaluating safety, tumor response, and duration of response. Because results are not posted and the design cannot provide a controlled comparison, it offers limited evidence for glecirasib.
Next expected readout: March 2027 · NCT05288205 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fulzerasib's landscape · Glecirasib's landscape